Vanguard Group Inc. Acquires 14,535 Shares of IDEAYA Biosciences, Inc. $IDYA

Key Points

• Vanguard Group Inc. increased its stake in IDEAYA Biosciences by 0.3%, purchasing an additional 14,535 shares, bringing its total ownership to approximately 5.81% valued at $83.4 million.
• Multiple hedge funds, including Mariner LLC and PNC Financial Services Group, have also raised their holdings in IDEAYA Biosciences, indicating strong institutional interest with 98.29% of the company's shares owned by institutional investors.
• Analysts' ratings for IDEAYA vary, with targets ranging from $25.00 by Goldman Sachs to $72.00 by JPMorgan, and a consensus rating of "Moderate Buy" with an average price target of $48.09.

Vanguard Group Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 0.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,092,619 shares of the company's stock after purchasing an additional 14,535 shares during the period. Vanguard Group Inc. owned about 5.81% of IDEAYA Biosciences worth $83,417,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Janus Henderson Group PLC grew its stake in shares of IDEAYA Biosciences by 13.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after purchasing an additional 695,263 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after acquiring an additional 142,000 shares in the last quarter. Fiera Capital Corp increased its position in shares of IDEAYA Biosciences by 2.1% in the first quarter. Fiera Capital Corp now owns 1,209,865 shares of the company's stock worth $19,818,000 after acquiring an additional 25,398 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of IDEAYA Biosciences by 22.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock worth $30,842,000 after acquiring an additional 220,000 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of IDEAYA Biosciences by 5.9% in the fourth quarter. Bank of America Corp DE now owns 747,934 shares of the company's stock worth $19,222,000 after acquiring an additional 41,390 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock traded down $0.09 on Thursday, reaching $24.91. The stock had a trading volume of 254,358 shares, compared to its average volume of 1,126,177. The business's 50-day moving average price is $23.14 and its two-hundred day moving average price is $20.43. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $40.25. The stock has a market cap of $2.18 billion, a P/E ratio of -6.57 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. During the same period last year, the firm earned ($0.68) EPS. The company's revenue was up NaN% compared to the same quarter last year. As a group, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target for the company in a report on Thursday, July 10th. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a "buy" rating for the company. JPMorgan Chase & Co. raised their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. Finally, Wells Fargo & Company assumed coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $47.10.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.